Suppr超能文献

肠道微生物群失调与心血管健康:机制与治疗潜力的综合综述

Gut Dysbiosis and Cardiovascular Health: A Comprehensive Review of Mechanisms and Therapeutic Potential.

作者信息

Trehan Shubam, Singh Gurjot, Bector Gaurav, Jain Prateek, Mehta Tejal, Goswami Kanishka, Chawla Avantika, Jain Aayush, Puri Piyush, Garg Nadish

机构信息

Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, IND.

Internal Medicine, Maharaj Sawan Singh Charitable Hospital, Beas, IND.

出版信息

Cureus. 2024 Aug 16;16(8):e67010. doi: 10.7759/cureus.67010. eCollection 2024 Aug.

Abstract

Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide. Recent research has identified gut dysbiosis - an imbalance in the gut microbiota - as a significant factor in the development of CVDs. This complex relationship between gut microbiota and cardiovascular health involves various mechanisms, including the production of metabolites such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs). These metabolites influence lipid metabolism, inflammation, and blood pressure regulation. In addition, the gut-brain axis and neurohormonal pathways play crucial roles in cardiovascular function. Epidemiological studies have linked gut dysbiosis to various cardiovascular conditions, highlighting the potential for therapeutic interventions. Dietary changes, probiotics, and prebiotics have shown promise in modulating gut microbiota and reducing cardiovascular risk factors. This underscores the critical role of gut health in preventing and treating CVDs. However, further research is needed to develop targeted therapies that can enhance cardiovascular outcomes.

摘要

心血管疾病(CVDs)是全球主要的死亡原因。最近的研究已确定肠道菌群失调——肠道微生物群失衡——是心血管疾病发展的一个重要因素。肠道微生物群与心血管健康之间的这种复杂关系涉及多种机制,包括三甲胺N-氧化物(TMAO)和短链脂肪酸(SCFAs)等代谢物的产生。这些代谢物会影响脂质代谢、炎症和血压调节。此外,肠脑轴和神经激素途径在心血管功能中起关键作用。流行病学研究已将肠道菌群失调与各种心血管疾病联系起来,凸显了治疗干预的潜力。饮食改变、益生菌和益生元已显示出调节肠道微生物群和降低心血管危险因素的前景。这强调了肠道健康在预防和治疗心血管疾病中的关键作用。然而,需要进一步研究以开发能够改善心血管结局的靶向治疗方法。

相似文献

3
Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.肠道微生物群及其代谢途径调节心血管疾病。
Front Microbiol. 2023 Sep 26;14:1272479. doi: 10.3389/fmicb.2023.1272479. eCollection 2023.
7
Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.调节肠道菌群作为 2 型糖尿病的治疗干预手段。
Front Endocrinol (Lausanne). 2021 Apr 7;12:632335. doi: 10.3389/fendo.2021.632335. eCollection 2021.
9
Gut microbiota and cardiovascular diseases axis.肠道微生物群与心血管疾病的关联。
Minerva Med. 2022 Feb;113(1):189-199. doi: 10.23736/S0026-4806.21.07527-3. Epub 2021 May 10.

本文引用的文献

7
Implication of Gut Microbiota in Cardiovascular Diseases.肠道微生物群在心血管疾病中的意义。
Oxid Med Cell Longev. 2020 Sep 26;2020:5394096. doi: 10.1155/2020/5394096. eCollection 2020.
9
Gut Microbiota and Cardiovascular Disease.肠道微生物群与心血管疾病。
Circ Res. 2020 Jul 31;127(4):553-570. doi: 10.1161/CIRCRESAHA.120.316242. Epub 2020 Jul 30.
10
Role of gut microbiota in cardiovascular diseases.肠道微生物群在心血管疾病中的作用。
World J Cardiol. 2020 Apr 26;12(4):110-122. doi: 10.4330/wjc.v12.i4.110.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验